Clinical Trial Update: Safety/Efficacy Study of Immunoconjugate With Docetaxel in Non-small Cell Lung Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 trial assessing the safety and efficacy of an immunoconjugate combined with docetaxel in non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Immunoconjugate with Docetaxel

Snippet

Sponsor: Seagen Inc. | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: COMPLETED